Quick Answer
X4 Pharmaceuticals, Inc reported Total Revenue of $35.11 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed an increase of +1,273.2% in Total Revenue from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $3.50 million | Q1 2019: $0.00 | Q2 2019: $0.00 | Q3 2019: $0.00 | Q1 2020: $3.00 million | Q2 2020: $0.00 | Q3 2020: $0.00 | Q1 2021: $0.00 | Q2 2021: $0.00 | Q3 2021: $0.00 | Q2 2023: $0.00 | Q3 2023: $0.00 | Q1 2024: $0.00 | Q2 2024: $563.0 thousand | Q2 2024: $563.0 thousand | Q3 2024: $560.0 thousand | Q3 2024: $560.0 thousand | Q1 2025: $28.81 million | Q2 2025: $1.97 million | Q3 2025: $1.77 million.
- Historical annual values: Fiscal year 2025: $35.11 million | Fiscal year 2024: $2.56 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2021: $0.00 | Fiscal year 2020: $3.00 million | Fiscal year 2019: $0.00 | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: